Omeros

Omeros is a Seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics. Its first FDA-approved product is Omidria® (phenylephrine and ketorolac injection) 1%/0.3% for use during lens replacement surgery. Omeros' pipeline includes five clinical-stage programs, a diverse group of preclinical programs, and additional drug-development platforms. http://www.omeros.com